CONSHOHOCKEN, PA — Madrigal Pharmaceuticals Inc. (Nasdaq: MDGL) reported its first profitable quarter as sales of its liver disease treatment Rezdiffra rose 50% to $431.3 million in the third quarter …
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.